THCT — Thc Therapeutics Share Price
Last trade - 00:00- $0.02m
- $0.75m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jul | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
THC Therapeutics, Inc. is focused on developing a sanitizing herb dryer, the dHydronator, with multiple design, function, and usage patents. The dHydronator product is specifically designed for the drying and sanitizing (i.e., reducing the bacterial count by using ultraviolet light) of freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator can reduce the moisture content of cannabis to 10-15% in only 10-14 hours. The dHydronator can also reduce the bacterial count of the cannabis during the drying process. The Company operates in the wellness industry.
Directors
- Brandon Romanek PRE (46)
- Victor Nacif OTH
- John Pierce OTH
- Natalia Tafur OTH
- Parker Mitchell DRC
- Fiorenzo Villani DRC (49)
- Last Annual
- July 31st, 2023
- Last Interim
- July 31st, 2023
- Incorporated
- May 1st, 2007
- Public Since
- December 7th, 2007
- No. of Shareholders
- 37
- No. of Employees
- 1
- Sector
- Machinery, Equipment & Components
- Industry
- Industrials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 34,146,149
- Address
- 11700 W CHARLESTON BLVD #73, LAS VEGAS, 89135
- Web
- https://thct.io/
- Phone
- +1 7026028422
- Auditors
- Gries & Associates, LLC
Upcoming Events for THCT
Similar to THCT
3DX Industries
Pink Sheets on Nasdaq
420 Property Management
Pink Sheets on Nasdaq
Abb
Pink Sheets on Nasdaq
Abound Energy
Pink Sheets on Nasdaq
AI Technology.
Pink Sheets on Nasdaq
FAQ
As of Today at 17:43 UTC, shares in Thc Therapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Thc Therapeutics last closed at $0.00 and the price had moved by +17.86% over the past 365 days. In terms of relative price strength the Thc Therapeutics share price has underperformed the S&P500 Index by -1.09% over the past year.
There is no consensus recommendation for this security.
Thc Therapeutics does not currently pay a dividend.
Thc Therapeutics does not currently pay a dividend.
Thc Therapeutics does not currently pay a dividend.
To buy shares in Thc Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Thc Therapeutics had a market capitalisation of $0.11m.
Here are the trading details for Thc Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: THCT
Based on an overall assessment of its quality, value and momentum Thc Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thc Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +298736.67%.
As of the last closing price of $0.00, shares in Thc Therapeutics were trading -88.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Thc Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Thc Therapeutics' management team is headed by:
- Brandon Romanek - PRE
- Victor Nacif - OTH
- John Pierce - OTH
- Natalia Tafur - OTH
- Parker Mitchell - DRC
- Fiorenzo Villani - DRC